# GLP-2 (Glucagon-Like Peptide-2) Dosage Protocol Guide: Gut Repair Research (2026)
> Research Use Only (RUO) Disclaimer: Native GLP-2 as a research peptide is not approved by the FDA for human use. Teduglutide (Gattex/Revestive), a GLP-2 analog, is FDA-approved only for short bowel syndrome under medical supervision. All research use of native GLP-2 should comply with applicable institutional and regulatory frameworks. Not for self-administration.
What Is GLP-2?
Glucagon-like peptide-2 (GLP-2) is a 33-amino acid peptide hormone secreted by intestinal L-cells in response to nutrient ingestion — particularly fats and carbohydrates. It belongs to the glucagon superfamily and is produced by post-translational processing of proglucagon, the same precursor that gives rise to glucagon and GLP-1.
GLP-2's primary biological function is intestinotrophic: it promotes the growth, proliferation, and survival of intestinal epithelial cells. Unlike GLP-1, which acts primarily on pancreatic beta cells and the brain to regulate glucose and appetite, GLP-2's actions are concentrated in the gastrointestinal tract — making it the dominant research target for gut barrier integrity, mucosal healing, and short bowel syndrome.
Mechanism of Action
GLP-2 exerts its effects via the GLP-2 receptor (GLP2R), a G-protein-coupled receptor expressed on intestinal subepithelial myofibroblasts, enteric neurons, and select immune cells. The downstream cascade includes:
- •cAMP/PKA pathway activation: Drives transcription of growth and survival factors including IGF-1 and keratinocyte growth factor (KGF)
- •IGF-1 upregulation: Stimulates intestinal crypt cell proliferation via paracrine IGF-1 signaling
- •Wnt/β-catenin signaling modulation: Promotes intestinal stem cell activity and villus elongation
- •Anti-apoptotic effects: Reduces enterocyte apoptosis rate, extending villus height and absorptive capacity
Net result: measurable increases in intestinal mass, villus height, crypt depth, and absorptive surface area — effects well-documented in preclinical models from rodents to swine to non-human primates.
GLP-2 vs Teduglutide: Key Differences
| Parameter | Native GLP-2 | Teduglutide (Gattex) |
|---|---|---|
| Structure | 33 amino acids, native sequence | Ala²-substituted GLP-2 analog |
| Half-life | ~7 minutes (rapid DPP-4 degradation) | ~2 hours (DPP-4 resistant) |
| Regulatory status | Research compound | FDA-approved for SBS |
| Research use | Acute mechanistic studies, DPP-4 interaction models | Long-duration gut repair studies |
| Dosing frequency | Multiple daily injections or continuous infusion | Once daily subcutaneous |
The short half-life of native GLP-2 (approximately 7 minutes) is a critical consideration for research protocol design. Dipeptidyl peptidase-4 (DPP-4) rapidly cleaves the N-terminal Ala-Gly dipeptide, inactivating the molecule. Researchers studying native GLP-2 must account for this in their administration schedule.
Reconstitution Protocol
GLP-2 is supplied as a lyophilized white powder. Standard reconstitution:
1. Solvent: Bacteriostatic water (0.9% benzyl alcohol in sterile water) is preferred; sterile water for injection is acceptable for single-dose experiments
2. Target concentration: 100–500 mcg/mL depending on study dose requirements
3. Procedure:
- Allow vial to equilibrate to room temperature (~20 minutes)
- Inject solvent slowly down the vial wall
- Gently roll between palms to mix — do not vortex
- Solution should be clear, colorless, and free of particulates
4. Storage:
- Lyophilized: –20°C, 24–36 months; avoid freeze-thaw cycles
- Reconstituted: 4°C for up to 7 days (BAC water); use within 24 hours (sterile water)
5. pH: GLP-2 is most stable at pH 4–5; avoid alkaline conditions
Research Dosing Ranges
Native GLP-2 (Short Half-Life Protocols)
Due to rapid DPP-4 inactivation, native GLP-2 research protocols require more frequent dosing:
Rodent models:
- •2.5–10 nmol/kg subcutaneous (typical range in intestinal adaptation studies)
- •Multiple daily injections (2–4×/day) to maintain biological effect, OR
- •Continuous subcutaneous infusion via osmotic mini-pump (most effective for chronic intestinal growth studies)
Acute mechanistic studies:
- •Single bolus: 10–100 nmol/kg to characterize peak receptor activation, cAMP kinetics, or early gene expression responses
- •Observe within 30–90 minute window post-injection for peak tissue effects
Human Research Equivalent Dosing (Teduglutide Reference)
FDA-approved teduglutide (Gattex) is dosed at 0.05 mg/kg/day subcutaneous in short bowel syndrome patients, which translates to approximately 3–5 mg/day in most adults. Research using native GLP-2 at human-equivalent doses must account for the markedly shorter half-life relative to teduglutide.
Research dosing guideline for human-equivalent studies:
- •Low range: 100–200 mcg per injection, 2–4× daily
- •Moderate range: 200–300 mcg per injection, 2–4× daily
- •High range: 300–400 mcg per injection, 2–4× daily
Note: These ranges are derived from the literature on native GLP-2 research and should not be interpreted as therapeutic dosing guidance.
Administration Routes
Subcutaneous Injection
The most commonly used route in clinical and preclinical GLP-2 research. In rodent studies, SC administration achieves approximately 60–80% bioavailability relative to IV, with peak plasma levels at 10–20 minutes post-injection.
Intravenous Infusion
Used in acute pharmacokinetic and mechanistic studies. Provides complete bioavailability and precise plasma level control. IV is the reference route for pharmacokinetic parameter determination.
Continuous Subcutaneous Infusion (Osmotic Pump)
Preferred for chronic intestinal adaptation studies in rodents. Maintains stable plasma levels, eliminating the pulse-dosing limitation of the short half-life. Particularly useful for studies examining villus hypertrophy, crypt proliferation, and mucosal mass changes over 1–4 weeks.
Research Application Protocols
Short Bowel Syndrome (SBS) Research Protocol
Model: Resection models in rodents or large animals
Duration: 2–4 weeks (post-resection adaptation phase)
Dosing: Continuous SC infusion at 2.5–10 nmol/kg/day or twice-daily SC injections
Primary endpoints: Intestinal length, villus height, crypt depth, enterocyte proliferation (Ki-67), absorptive function (xylose absorption test)
Controls: Sham-operated and vehicle-treated resected animals
Gut Barrier Integrity Protocol
Application: Investigating GLP-2's role in tight junction protein expression (claudin, occludin, ZO-1) and paracellular permeability
Duration: 1–2 weeks
Dosing: Once or twice daily SC injection at 10 nmol/kg (rodent models)
Endpoints: FITC-dextran permeability assay, western blot for tight junction proteins, intestinal inflammation markers (IL-6, TNF-α, IL-1β)
Inflammatory Bowel Disease (IBD) Research Protocol
GLP-2 has demonstrated anti-inflammatory effects in colitis models. Typical protocol:
- •Model: DSS-induced colitis (rodent) or TNBS colitis
- •Treatment initiation: 24–48 hours post-colitis induction
- •Duration: 7–14 days
- •Dosing: 10–25 nmol/kg twice daily
- •Endpoints: Disease activity index, histological scoring, cytokine profiling, mucosal healing assessment
Pharmacokinetics: Native GLP-2 vs Teduglutide
Understanding GLP-2's pharmacokinetics is critical for protocol timing:
| Parameter | Native GLP-2 | Teduglutide |
|---|---|---|
| Half-life (plasma) | 7 minutes | ~2 hours |
| Tmax (SC) | 10–20 min | 3–5 hours |
| Bioavailability (SC) | ~70% | ~60% |
| DPP-4 susceptibility | High | Resistant (Ala² substitution) |
| Steady state | N/A (multiple daily dosing) | 3–4 weeks |
| Duration of biological effect | 1–2 hours post-injection | 8–12+ hours |
Safety Profile and Research Monitoring
In both preclinical and clinical studies, GLP-2 has demonstrated a favorable safety profile with effects confined primarily to the gastrointestinal tract:
GI effects to monitor:
- •Increased intestinal motility (may manifest as loose stools at higher doses)
- •Intestinal polyp growth (observed with long-term teduglutide administration in clinical settings — monitor in chronic animal studies)
- •Increased intestinal fluid secretion
Systemic effects:
- •Mild and transient nausea at initiation in human studies
- •No clinically significant cardiovascular effects reported
- •No adverse hepatic or renal signals in clinical pharmacology studies
Contraindicated concurrent models:
- •Do not combine with active GI malignancy models; GLP-2's pro-proliferative effects on intestinal epithelium are a theoretical oncological concern in carcinoma models
Cycling Framework
For chronic gut repair research:
- •Active treatment period: 2–8 weeks (aligned with intestinal adaptation timescale)
- •Assessment point: End of treatment + 1 week recovery measurement recommended to distinguish pharmacological effect from sustained tissue remodeling
- •Washout: Native GLP-2 clears within 1–2 hours; structural tissue effects (villus height, mucosal mass) may persist 1–2 weeks after cessation
Related Research Articles
- •GLP-2 Complete Research Profile — Intestinotrophic Hormone
- •GLP-1 vs GLP-2: Mechanism Differences and Research Applications
- •Teduglutide (Gattex): FDA-Approved GLP-2 Analog Research Profile
- •BPC-157 vs KPV vs LL-37: Gut Healing Peptides Comparison
---
This article is for educational and research informational purposes only. Native GLP-2 as a research compound is not approved for human therapeutic use. All research must comply with applicable institutional, local, and international regulations.